RE: Start of NEXT BULL CYCLE!25 Feb 2022 14:10
can a delaware company make it ,
Suzy full of confidence!
" Xtandi, a wonder drug for prostate cancer, was developed at UCLA with substantial funding from the taxpayers through the Pentagon and the National Institutes of Health.
UCLA has profited handsomely from the drug, to the tune of more than $520 million in royalties. The drug companies that acquired the manufacturing license, including Pfizer and the Tokyo firm Astellas Pharma, have also raked in billions in sales.
American taxpayers and prostate cancer patients haven’t done as well. Xtandi’s average wholesale price in the U.S. comes to $189,800 a year. "
Feb. 10, 2022
Michael Hiltzik